drug · intermediate · partly written
Axicabtagene ciloleucel (Yescarta)
Axicabtagene ciloleucel is an autologous CD19-directed CAR T cell product approved for refractory large B-cell lymphoma.
Also called: axi-cel, Yescarta
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
What it is in one breath
A CD19 CAR T product for adults with refractory large B-cell lymphoma. In the ZUMA-1 trial 82% of 101 treated patients responded and 54% had a complete response, with serious cytokine release and neurologic events in a minority. 1
Reported, not yet replicated
The decisive trial: ZUMA-1 more
ZUMA-1 was a multicentre phase 2 trial in 111 patients with refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or transformed follicular lymphoma. The product was manufactured for 110 and administered to 101 after low-dose cyclophosphamide plus fludarabine. Response was 82% and complete response 54%. At median follow-up of 15.4 months, 42% continued to respond; overall survival at 18 months was 52%. Higher CAR T levels in blood were associated with response.
The FDA review reports lower figures from the independent review committee than the investigator-assessed ones above: 72% objective and 51% complete. Trials were single arm; FDA judged historical comparison adequate (SCHOLAR-1, as quoted in the review). 12
Reported, not yet replicated
Compared with tisagenlecleucel deep
Both are autologous CD19 products that carry a CD3 zeta signal. Axi-cel uses a gamma-retroviral vector and a CD28 costimulatory domain; tisagenlecleucel uses a lentiviral vector and 4-1BB, which FDA describes as important for persistence. The trials are in different diseases and age groups, so their rates are not comparable. 23
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Nct zuma1
NCT02348216
Mechanism
The patient's T cells are engineered with a gamma-retroviral vector to carry a CD19-binding mouse-derived antibody fragment with CD3 zeta and a CD28 costimulatory domain, expanded, and infused after cyclophosphamide plus fludarabine conditioning. Binding CD19 activates the cell to kill and divide. 2
Reported, not yet replicated
Delivery route
Must survive
Side effects
Cytokine release syndrome and neurologic events
Grade 3 or higher CRS in 13% and neurologic events in 28% of patients in ZUMA-1; three patients died during treatment. The FDA review states that fatal and life-threatening events occurred and that serious or fatal cerebral edema was reported in a safety update. 12
Reported, not yet replicated
Blood count falls
Grade 3 or higher neutropenia 78%, anemia 43%, thrombocytopenia 38%. 1
Reported, not yet replicated
Verdict
Outcome
worked
Why
In ZUMA-1 (phase 2, single arm, 111 enrolled, 101 treated) the objective response rate was 82% and complete response 54%; at a median 15.4 months of follow-up 42% still had a response; survival at 18 months was 52%. The independent committee gave lower figures (72% objective, 51% complete) than investigators. FDA approved it on 18 Oct 2017. 12
Reported, not yet replicated
Teach this
In one sentence
Axi-cel is the patient's own T cells fitted with a CD19-seeking receptor with a CD28 signal, used in refractory large B-cell lymphoma. 1
Reported, not yet replicated
The common wrong idea
The headline 82% is how many patients the drug cured.
It is an objective response rate in a single-arm trial, which counts partial responses, and the independent committee's figures were lower than the investigators'.
The one citation to hand over: 1
Still open here
- Long-term durability beyond the 15.4-month follow-up of the opened abstract was not read.
- Label text and boxed warning were not read; only the FDA review and an abstract.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Neelapu, S. S., et al.. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine (2017). paper; opened 2026-11-17 all records citing this
- FDA Summary Basis for Regulatory Action: Yescarta (axicabtagene ciloleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Maude, S. L., et al.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine (2018). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2017
- Regulatory status
- approved
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/drugs/axicabtagene-ciloleucel.json